Attorney General Sam Olens announced today that the State of
Detrol was FDA approved in March 1998 for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. The settlement resolves allegations that Pfizer’s promotional activities were designed by the company to increase the prescribing of Detrol for uses in men for which it was not approved. These uses included treatment for benign prostate hyperplasia, bladder outlet obstruction and lower urinary tract symptoms. The investigation began with a whistleblower lawsuit filed by two former Pfizer employees, the relators, in U.S. District Court in
The settlement is the result of a joint investigation by the United States Attorney’s Office for the District of Massachusetts, the U.S. Department of Justice, the relators’ attorneys, and a State Team of representatives from the Medicaid Fraud Control Units. The total value of the national civil settlement is $14 million, with $5,576,923.00 designated as Medicaid program recovery. The remaining portion of the civil recovery is for damages to federally-funded health care programs (Medicare, TRICARE and the Department of Defense).